Dyslipidemias
Conditions
Keywords
Mixed dyslipidemia
Brief summary
The goal of this clinical trial is to learn if drug RBD5044 works to treat mixed dyslipidemia in adults. It will also learn about the safety of drug RBD5044. The main questions it aims to answer are: Does drug RBD5044 reduce the triglyceride levels? What medical problems may participants experience when taking drug RBD5044? Researchers will compare drug RBD5044 to a placebo to see if drug RBD5044 works to treat mixed dyslipidemia. Participants will: Receive RBD5044 or placebo twice during the trial (Day 1 and Day 84). Visit the clinic 11 times during 12 months (visit every 4-8 weeks) for checkups and tests.
Detailed description
This is a multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase 2 clinical trial to evaluate the efficacy and safety of RBD5044 subcutaneous injections in participants with mixed dyslipidemia. There will be 3 different dose level groups of RBD5044 or placebo: low dose (n=40), medium dose (n=40) or high dose (n=40). Within each of the 3 dose cohorts, participants will be randomly assigned in a 3:1 ratio to either active (RBD5044) treatment or to placebo treatment. All trial groups will be dosed in parallel. All participants will be dosed at their trial site and undergo blood sampling and examinations at pre-defined timepoints. Participants will be followed-up for 48 weeks from the first day of IMP/placebo administration. Primary endpoint evaluation will take place in week 16. End of trial is in week 48.
Interventions
DRUGRBD5044
RBD5044, active drug.
DRUGPlacebo
Placebo that is identical in appearance and volume to the doses of active IMP.
Sponsors
Ribocure Pharmaceuticals AB
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Quadruple (participant, care provider, investigator, outcomes assessor)
Intervention model description
Double-blind, placebo-controlled clinical trial
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Willing to comply with protocol required visit schedule and visit requirements and provide written informed consent. * Male or female participants, aged 18 to 80 years inclusive. * Fasting TG level of ≥ 150 mg/dL (≥ 1.69 mmol/L) and \<499 mg/dL (5.61 mmol/L). * Fasting levels at screening of non-HDL-C ≥ 100 mg/dL (2.59 mmol/L), or low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL (1.8 mmol/L) after at least 4 weeks of stable diet and stable optimal statin therapy (+ or - ezetimibe) if indicated. * Body mass index between 18 and 40 kg/m2.
Exclusion criteria
* Any uncontrolled or serious disease, or any medical or surgical condition, that may interfere with participation in the clinical trial and/or put the participant at significant risk (according to the investigator's judgment) if he/she participates in the clinical trial. * Uncontrolled hypertension (blood pressure \>160/100 mmHg at screening). (If untreated, participant may be re-screened once hypertension is treated and controlled). * Active or history of serious mental illness or psychiatric disorder, including but not limited to schizophrenia, bipolar disorder, or severe depression, which require current pharmacological intervention. Participants with a history of severe depression who are no longer on medication. * Any of the following laboratory values at screening: Hepatic: ALT or AST \>2× ULN at screening, eGFR \<30 mL/min/1.73 m2 (using the Modification of Diet in Renal Disease \[MDRD\] equation) at Screening, HbA1c \>9.0% (or \>75 mmol/mol International Federation of Clinical Chemistry \[IFCC\] units) at screening. * Patients with a diagnosis of HBV, HCV or HIV at screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in triglyceride (TG) levels at week 16 | From baseline until end week 16 | Percent change from baseline in TG levels at week 16. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency, intensity and seriousness of the AEs during the trial | Each visit from baseline to week 48 (end of trial) | Number and percentage of participants with AEs. All reported AE terms will be coded using Medical Dictionary for Drug Regulatory Affairs (MedDRA). |
| Change from baseline in triglyceride (TG) levels at different time points | week 4, 8, 12, 20, 24, 32, 40 and 48 | Percent change from baseline in TG levels at different time points |
| Change from baseline in ApoC-III levels at different time points | week 4, 8, 12, 20, 24, 32, 40 and 48 | Percent change from baseline in ApoC-III levels at different time points |
| Plasma concentrations of RBD5044 | In conjunction of administration of the IMP | — |
| Change from baseline in lipid parameters levels at different time points | week 4, 8, 12, 16, 20, 24, 32, 40 and 48 | Percent change from baseline in TC, LDL-C, HDL-C, non-HDL-C, TRL-C, ApoB, ApoA1, Lp (a) levels at different time points |
Countries
Sweden
Contacts
CONTACTRebeckha Magnusson
PRINCIPAL_INVESTIGATORSara Svedlund, MD, PhD
Ribocure Clinic/Ribocure Pharmaceuticals AB
PRINCIPAL_INVESTIGATORDavid Erlinge, MD, PhD
Lunds Universitetssjukhus
PRINCIPAL_INVESTIGATOREmil Hagström, MD, PhD
Akademiska Sjukhuset Uppsala
PRINCIPAL_INVESTIGATORÅke Olsson, MD, PhD
AkardoMedSite
Outcome results
None listed